Usted está aquí
Chemotargets and FDA to improve drug safety assessments
Chemotargets, located at the Barcelona Science Park, and the Food and Drug Administration's Center for Drug Evaluation and Research (FDA/CDER) will work together under a 5-year research collaboration agreement. The primary objective of the agreement will be to assess the utility and performance of the Chemotargets Clarity® intelligence & discovery platform to predict on-target and off-target activities using known pharmacology and safety data from experimental studies of small molecular entities.
Founded on 2006 as a spin-off company from Dr. Mestres’ Systems Pharmacology lab of the IMIM Hospital del Mar Medical Research Institute, Chemotargets offers cutting-edge validated computational methodologies with top-market predictive performance. The innovation strategy is driven by access to state-of-the-art research performed at Dr. Mestres Lab, a leading academic center of excellence based in Barcelona.
More information is available on the Chemotargets website.
Photo: Dr. Jordi Mestres, Founder and CEO of Chemotargets